NVO•benzinga•
Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review
Summary
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Novo Nordisk's application for once-weekly insulin icodec on May 24. Concerns include an increased risk of hypoglycemia in type 1 diabetes patients.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 22, 2024 by benzinga